Analysis and commentary include discussion of the patent and product portfolio coverage of key companies. There are significant research and product development areas where leading companies lack coverage.
Investigation of assignee by technology group and forward citations of key patents provides insight into the large number of players and identifies potential targets for acquisition.
The patent holding and status of the following companies is covered in great detail:
Abbott Arkray Bayer Becton Dickinson DexCom Insulet J&J Medtronic Nipro Novo Nordisk Roche Sanofi-aventisThis unprecedented combination of market, technology, and intellectual property information will provide a detailed look at the market and devices in this space as well as provide a perspective of the challenges and opportunities associated with diabetes. CONTENTS EXECUTIVE SUMMARYVolume I 1Current Technologies .2Geographic Trends .2Volume II .2Intellectual Property Trends .3Technology Trends .3VOLUME I - DIABETES INDUSTRY ANALYSIS1.0 MARKET OVERVIEW 71.1 BACKGROUND 71.1.1 Diagnosis and Management of Diabetes .8Insulin-Dependant Diabetes Patients .9Current Trends in Diabetes Care ..91.2 THE GLOBAL DIABETES BURDEN .101.2.1 Diabetes Prevalence 10Fig.1.0: Diabetes Prevalence by Geographic Region, 2011-2030 .11Diabetes Prevalence for the Top 10 Countries, 2011-2030 (million) 11Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group Study .121.2.2 Mortality .121.2.3 Diabetes Complications 131.2.4 The Cost of Diabetes 141.3 THE DIABETES DEVICE MARKET ..151.3.1 Product Segments .16Fig.1.2: Diabetes Device Market by Major Product Category, 2011 .16Fig.1.3: Percentage of US Diabetes Patients by Treatment Type, 2007-2009 .17Fig.1.4: Diabetes Device Market by Product Type, 2011 181.3.2 Current Market Trends 19Fig.1.5: Global Diabetes Device Market, 2011 (US$ billion) .19Global Diabetes Market by Product Type, 2005-2011 (US$ million) ..20Fig.1.6: Global Diabetes Market By Product Type, 2005-2011 (US$ billion) 20Global Diabetes Market Growth Rates by Product Type, 2006-2011 (%) .21Fig.1.7: Global Diabetes Device Market Growth Rates, 2006-2011 (%) ..211.3.3 Regional Perspective 21Fig.1.8: Global Diabetes Device Market by Region, 2011 .22Fig.1.9: US Market by Product Type, 2011 ..22Fig.1.10: European Market by Product Type, 2011 23Fig.1.11: Other Regions by Product Type, 2011 .231.4 COMPETITIVE ENVIRONMENT 24Fig.1.12: Diabetes Device Market Share by Company, 2011 .25Key Companies' Diabetes Care Sales, 2005-2011 (US$ million) ..25Non-US Companies' Diabetes Sales in Reported Currency, 2005-2011 (million) 25Leading Companies' International Diabetes Care Sales, 2005-2011 (US$ million) ..26Leading Companies' US Diabetes Care Sales, 2005-2011 (US$ million) ..261.4.1 New Market Entrants .261.4.2 Market Withdrawals 271.4.3 Rounding Out Product Portfolios 28Key Companies: Market Presence & Position by Product Area .28Key Companies: Current & Future Potential Market Presence by Product Area ..291.4.4 Market Consolidation ..291.5 GROWTH DRIVERS, RESTRAINTS AND FUTURE OPPORTUNITIES ..301.5.1 Regulatory and Reimbursement Environment 311.5.2 Connectivity and Data Integration 32The Role of Telemonitoring in Diabetes Care .32Safety Issues 331.5.3 Emerging Technologies .34New-Generation Insulin Delivery Devices .34Development of a Closed-Loop System .35Rival Technologies .351.6 MARKET EXPECTATIONS ..38Fig.1.13: Global Diabetes Device Market, 2011-2017E (US$ billion) 38Global Diabetes Market Forecast by Product Type, 2011-2017E (US$ million) 39Global Diabetes Market Forecast Growth Rates by Product, 2011-2017E (%) 39Fig.1.14: Global Monitoring Market Forecast, 2011-2017E (US$ billion) .39Fig.1.15: Global Insulin Delivery Market Forecast, 2011-2017(E) (US$ billion) 40Fig.1.16: Diabetes Device Market by Product, 2017E .402.0 DIABETES MONITORING PRODUCTS .41Overview: Glucose Monitoring Products ..422.1 MARKET DYNAMICS .44Fig.2.1: Global Glucose Monitoring Market, 2005-2011 (US$ billion) 44Fig.2.2: Global Blood Monitoring Market Growth, 2005-2011 (%) ..44Fig.2.3: Glucose Monitoring Market by Product Type, 2011 ..45Fig.2.4: Blood Glucose Testing Market by Geographic Region, 2011 .45Public Companies' Glucose Monitoring Sales, 2005-2011 (US$ million) 45Fig.2.5: Glucose Monitoring Market Shares by Company, 2011 .462.2 MANUAL SELF-MONITORING BLOOD GLUCOSE PRODUCTS 47Fig.2.6: Example of a Classic BGM & Test Strip: Bayer's Contour Meter .482.2.1 Current Market Environment . 48Fig.2.7: Global SMBG Market, 2005-2011 (US$ million) .49Fig.2.8: Global SMBG Market Growth Rates, 2005-2011 (%) .49Fig.2.9: SMBG Market by Product Type, 2011 ..49Regional Markets and Reimbursement 50Fig.2.10: SMBG Market by Region, 2011 50Market Developments 51Fig.2.11: Mendor's Discreet (left) & Roche's Accu-Check Mobile with Attached Lancing Device (right) .51Fig.2.12: BodyTel Europe's GlucoTel BGM ..51Fig.2.13: Medisana's GlucoDock Attached to an Apple iPhone .52Accuracy Standards ..53Market Forecast 54Summary: SMBG Growth Drivers, Restraints & Opportunities ..55Fig.2.14: Global SMBG Market, 2011-2017E (US$ billion) .55Fig.2.15: Global SMBG Market Growth Rates, 2012-2017E (%) ..562.2.2 Competitive Environment 56Public Companies' BGM Sales, 2005-2011 (US$ million) .57Fig.2.16: SMBG Market Share by Company, 2011 .57Fig.2.17: United States SMBG Market Share by Company, 2011 .58Fig.2.18: SMBG International Market Share by Company, 2011 582.2.3 Market-Leading Self-Testing Blood Glucose Meters 591. Abbott's Blood Glucose Monitors 592. Arkray's Glucocard Products .603. Bayer's Blood Glucose Monitoring Systems 614. ContourUSB 625. Contour, Contour TS, Contour Link and Breeze 2 626. DIDGET Meter ..637. Elite and Elite XL .63LifeScan OneTouch Products 63Nipro Diagnostics' TRUE Products 66Roche Diabetes Care's Products 672.2.4 Other Market Participants 68Competing Self-Testing Blood Glucose Monitoring Products 68Product Highlights .712.2.5 Products in Development .77Intuity Medical's POGO Blood Glucose Monitoring System 77Pepex Biomedical's Trio Products .772.3 CONTINUOUS GLUCOSE MONITORING 78Fig.2.19: Example of a CGM: Medtronic's Guardian REAL-Time System .782.3.1 The Benefits of CGM 782.3.2 Barriers to Adoption .79The Cost of CGM 792.3.3 Clinical Trial Results - Highlighting Benefits and Drawbacks .792.3.4 The TD1 Exchange: User Experiences of CGM 812.3.5 CGM Market Trends and Opportunities 82Fig.2.20: Global CGM Market, 2006-2011 (US$ million) 82Fig.2.21: Percentage of CGM Sales Volumes by Hardware & Consumables, 2011 82Regional Adoption Rates, Regulatory and Reimbursement Environment .83Fig.2.22: CGM Market by Region, 2011 83Future Prospects ..84Fig.2.23: Global CGM Market Forecast, 2011-2017E (US$ million) 85Fig.2.24: Global CGM Market Forecast Growth Rates, 2011-2017E (%) .86Summary: CGM Benefits, Challenges & Opportunities ..862.3.6 Competitive Environment 87Leading Companies' Reported CGM Sales, 2006-2011 (US$ million) 87Fig.2.25: Global CGM Market Shares by Company, 2011 88Fig.2.26: US CGM Market Shares by Company, 2011 .88Fig.2.27: International CGM Market Shares by Company, 2011 .892.3.7 Currently-Available Products 89Medtronic's Guardian REAL-Time CGM System .89DexCom's CGMs 90Abbott's FreeStyle Navigator .91A Menarini Diagnostics' GlucoDay S 922.3.8 Products in Development .92Abbott's Navigator II .92DexCom's Research and Development 92New-Generation Implantable CGM Sensors .93Minimally-Invasive CGM in Development .952.4 NON-INVASIVE GLUCOSE MONITORING ..1002.4.1 Competitive Environment .. 1002.4.2 AIMEDICS' HypoMon .1012.4.3 Biosign Technologies' UFIT TEN-20 Non-Invasive Blood Pressure and Glucose Meter 1012.3.4 Biovotion's Multisensor Glucose Monitoring System 1022.3.5 Integrity Applications' GlucoTrack .103Clinical Study Results .1032.3.6 Optical Technologies ..105C8 MediSensors Optical Glucose Monitor ..105EyeSense's Optical Sensor 105Freedom Meditech's I-SugarX Glucose Monitoring System .106Grove Instruments' Grove Glucometer ..106Lein Applied Diagnostics ..107LighTouch Medical's Non-Invasive Glucose Monitor .107 Massachusetts Institute of Technology's Raman Spectroscopy System .108Medtronic's PreciSense Technology ..108OrSense's NBM-200G Non-Invasive Blood Glucose Meter 108St Louis Medical Devices Near-Infrared Light-Based System .109Smart Tattoos 1092.3.7 Tear Fluid Glucose Sensors ..110Mayo Clinic, Arizona State University and BioAccel .110 University of Washington and Microsoft Research .111The University of Western Ontario's Glucose Monitoring Contact Lenses .1112.3.8 Breath-Based Glucose Monitoring 112PositiveID's EasyChek .112Xhale's Breath-Based Glucose Monitor 112 Brown University and Saliva-Based Glucose Testing .1123.0 INSULIN DELIVERY PRODUCTS ..1143.1 ADDRESSABLE PATIENT POPULATION .116Fig.3.1: Percentage of US Diabetes Patients by Treatment Type, 2007-2009 1163.2 MARKET TRENDS .117Insulin Delivery Market by Product Type 2005-2011 (US$ million) ..117Fig.3.2: Global Insulin Delivery Market, 2005-2011 (US$ billion) .117Fig.3.3: Global Insulin Delivery Market Growth Rates, 2006-2011 (%) .118Fig.3.4: Percentage of Insulin Delivery Market by Product Type, 2011 .118Fig.3.5: Insulin Delivery Market by Geographic Region, 2011 ..1193.2.1 Competitive Environment 120Key Companies' Insulin Delivery Sales, 2006-2011 (US$ million) 120Fig.3.6: Insulin Delivery Market Share by Company, 2011 ..1203.3 FUTURE MARKET PROSPECTS ..121Summary: Insulin Delivery Market Growth Drivers, Restraints & Opportunities .121Insulin Delivery Market Forecast by Product Type 2011-2017E (US$ million) 122Fig.3.7: Global Insulin Delivery Market Forecast, 2011-2017 (US$ billion) ..122Fig.3.8: Global Insulin Delivery Market Estimated Growth Rates, 2012-2017 (%) .122Fig.3.9: Estimated Insulin Delivery Market by Product Type, 2017 ..1233.4 MANUAL INSULIN INJECTION PRODUCTS .124Fig.3.10: Manual Insulin Delivery Method by Product Type, 2011 ..124Fig.3.11: Percentage of Novo Nordisk Insulin Sold in Pens by Region, 2011 125Fig.3.12: Manual Insulin Delivery Market by Geographic Region, 2011 .1253.4.1 Insulin Pens 126Fig.3.13: Example Insulin Pen: Novo Nordisk's NovoPen 4 ..126Fig.3.14: Global Insulin Pen Market: Disposable vs Reusable Pens, 2011 .126Competitive Environment 127Fig.3.15: Insulin Pen Use by Manufacturer, 2011 127Currently-Available Products ..1283.4.2 Needles and Syringes .130Fig.3.16: Insulin Needles & Syringes Market by Manufacturer, 2011 131Pen Needles .1313.5 INSULIN PUMPS ..133Fig.3.17: Example Insulin Pump: Medtronic's MiniMed Paradigm REAL-Time Revel 133Fig.3.18: Example Insulin Pump: Roche's Accu-Check Spirit .133Insulin Pump Market: Growth Drivers, Restraints & Opportunities 1343.5.1 The TD1 Exchange: User Experiences of CGM .1353.5.2 Current Market Trends 136Fig.3.19: Global Insulin Pump Market, 2005-2011 (US$ million) 136Fig.3.20: Global Insulin Pump Market Growth Rates, 2006-2011 (%) 136Fig.3.21: Insulin Pump Market by Product, 2011 137Regional Perspective 137Fig.3.22: Insulin Pump Market by Region, 2011 .137Fig.3.23: Insulin Pump Adoption Rates for Type 1 Diabetes Patients by Key Country, 2010 (%) ..138Regulatory Environment - FDA Infusion Pump Improvement Initiative .139Negative Publicity and the Potential for Cyber Attacks 140Market Outlook 141Fig.3.24: Global Insulin Pump Market Forecast, 2011-2017 (US$ million) ..141Fig.3.25: Global Insulin Pump Market Estimated Growth Rates, 2012-2017 (%) 1413.5.3 Competitive Environment 142Key Companies' Insulin Pump Sales, 2005-2011 (US$ million) 142Fig.3.26: Insulin Pump Market Shares, 2011 .1433.5.4 Currently-Available Insulin Pumps 143Animas Insulin Pumps ..143Asante Solutions' Pearl Insulin Pump 144D Medical Industries' Spring Pumps and Infusion Sets .144Medtronic's MiniMed Paradigm Revel Insulin Pump and Infusion Sets ..145Sooil Development's Diabecare Insulin Pumps 146Roche Insulin Pumps .146Tandem Diabetes Care's t:slim Insulin Delivery System .147Insulin Delivery Patch Pumps ..1473.5.5 Products in Development .150Becton Dickinson-JDRF Micro-Needle Technology ..150CeQur's Insulin Patch Infuser ..150D Medical Industries' Spring Hybrid Patch Pump .150Debiotech's JewelPUMP 151Insulet's Second-Generation OmniPod ..151Insuline Medical's InsuPatch and InsuPad 151Roche's SOLO Micropump 1523.6 ALTERNATIVE INSULIN DELIVERY DEVICES 1533.6.1 Generex Biotechnology's Oral-lyn ..1533.6.2 Insulin Inhalers .154Development Considerations .154Fig.3.27: MannKind's Dreamboat (Gen2) Insulin Inhaler 1554.0 COMBINED CGM-INSULIN PUMP SYSTEMS .1574.1 CURRENTLY-AVAILABLE PRODUCTS .1584.1.1 Medtronic's Paradigm Integrated Diabetes Management Products 158Paradigm REAL-Time Revel 158Fig.4.1: MiniMed Paradigm REAL-Time System ..158Enlite CGM Sensor ..159Clinical Trials ..159ONSET Study .160REAL Trend Study 1604.1.2 Animas Vibe .1614.2 PRODUCTS IN DEVELOPMENT ..1624.2.1 D Medical Industries' Combined CGM-Pump System 1625.0 ARTIFICIAL PANCREAS TECHNOLOGY .1635.1 SEMI-CLOSED LOOP SYSTEMS ..1655.1.2 Medtronic's Paradigm Veo System with Low Glucose Suspend .165Fig.5.1: Medtronic's Paradigm Veo System with Low Glucose Suspend .165ASPIRE Study 1665.2 RESEARCH & DEVELOPEMNT 1675.2.1 FDA Artificial Pancreas Development Guidelines .1675.2.2 Key Closed-Loop Development Projects .168The Juvenile Diabetes Research Foundation's Artificial Pancreas Project .168Mayo Clinic .172UC Santa Barbara, Sansum Diabetes Research Institute, Mayo Clinic, Universities of Virginia & Padova 172AP@home Project 172MD-Logic Artificial Pancreas System .173Medtronic's Closed-Loop System .174 Rensselaer Polytechnic Institute .1756.0 POC MANUFACTURERS ..1766.1 POC COMPANY DIRECTORY ..1766.2 LEADING COMPANY PROFILES .1846.2.1 Abbott Laboratories ..184Recent Key Events .184Blood Glucose Monitors 185In Development - Navigator II CGM System .186Alliance with Insulet .187Litigation ..187Financial Performance .188Abbott Diabetes Care Sales by Region, 2006-2011 (US$ million) 188Fig.6.1: Percentage of Abbott Diabetes Care Revenue by Region, 2011 .1886.2.2 Arkray ..189Recent Key Events .189Blood Glucose Self-Testing .189Current Alliances and Contracts 1916.2.3 Bayer .192Recent Key Events .192Blood Glucose Monitoring Systems 192Current Alliances .194Litigation 195Financial Performance .195Bayer Diabetes Care Revenue, 2005-2011 (EUR million) 1956.2.4 Becton, Dickinson and Company .196Recent Key Events .196BD Diabetes Care Products .196Collaboration with the JDRF 197Litigation with Insulet ..197Financial Performance .197BD Diabetes Care Sales by Region, 2006-2011 (US$ million) 198Fig.6.2: Percentage of BD Diabetes Care's Revenue by Region, 2011 1986.2.5 DexCom .199Recent Key Events .199SEVEN PLUS CGM System ..200GlucoClear 201Research and Development .201SweetSpot Diabetes Care Acquisition 201Current Alliances .202Litigation with Abbott .203Financial Performance .204DexCom - Operating Results, 2007-2011 (US$ thousands) .2056.2.6 Insulet .206Recent Key Events .207OmniPod Insulin Management System .207Current Alliances .208Acquisition of Neighborhood Diabetes .209Litigation with Becton, Dickinson and Company .209Financial Performance .209Insulet - Operating Results, 2007-2011 (US$ thousands) .2106.2.7 Johnson & Johnson .211Recent Key Events .211Animas Operations .212LifeScan Operations 214Financial Performance ..217J&J Diabetes Care Revenue, 2006-2011 (US$ million) .218Fig.6.3: J&J Diabetes Care Sales by Region, 2011 .218Fig.6.4: J&J Diabetes Care Sales, 2004-2011 (US$ million) .2186.2.8 Medtronic .219Recent Key Events .219Integrated Diabetes Management Products ..220Guardian REAL-Time CGM System 221iPro Professional Use CGM Products ..222Enlite CGM Sensor ..222MiniMed Paradigm Revel Insulin Pump and Infusion Sets ..222CareLink Software ..223Blood Glucose Meters ..223Clinical Trials ..224Research and Development .225Alliance with Bayer 225Financial Performance .226Fig.6.5: Medtronic Diabetes Revenue, 2005-2011 (US$ million) 226Medtronic - Diabetes Sales by Region, 2008-2011 (US$ million) .227Fig.6.6: Medtronic Diabetes Revenue by Region, 2011 227Fig.6.7: Medtronic Diabetes Revenue by Product Type, 2010* .2276.2.9 Nipro Diagnostics 229Recent Key Events .229Blood Glucose Monitoring Products .230Blood Glucose Monitors .230 6.2.10 Roche Diabetes Care 232Recent Key Events .232Diabetes Care Products 233Accu-Chek Combo BGM and Pump System .234Insulin Pumps 234Data Management Tools 235In Development - SOLO Micropump ..235Current Alliances and Contracts ..236Litigation 236Financial Performance .237Roche Diabetes Care Sales by Product, 2010-2011 (SFr million) 237Roche Diabetes Care Sales by Region, 2006-2011 (SFr million) .237Fig.6.8: Roche Diabetes Care - Revenue by Product Line, 2011 238Fig.6.9: Roche Diabetes Care - Revenue by Region, 2011 .238 6.2.11 Ypsomed 239Recent Key Events .239mylife Diabetes Care Products .240Ypsomed Delivery Systems 240Acquisition of ICU Medical's Orbit Infusion Set Business .241Current Alliances .241Financial Performance .242Ypsomed - Operating Results, Y/E 31st March 2007-2011 (SFr millions) 243Ypsomed - Results by Business Segment, Y/E 31st March 2009-2011 (SFr millions) ..243Ypsomed - Revenue by Geographic Region, Y/E 31st March 2009-2011 (SFr millions) 244Fig.6.10: Ypsomed - Revenue by Business Segment, Fiscal 2010 .244Fig.6.11: Ypsomed - Revenue by Geographic Location, Fiscal 2010 2457.0 APPENDICES 2467.1 LIST OF ABBREVIATIONS 2467.2 - REPORT METHODOLOGY 247Sources ..247Market forecasts 248VOLUME II - DIABETES TECHNOLOGY AND INTELLECTUAL PROPERTY ANALYSIS1.0 SUMMARY 251Figure 1.1 – Diabetes Landscape by Technology 252Figure 1.2 – High Level Overview of Diabetes Patent Activity .254Figure 1.3 – Bar Chart of Totals for each Technology Group .255Figure 1.4 – Top 20 Assignees Patents from this Study 256Figure 1.5 - Blood Extraction by Priority Date by Assignee .257Figure 1.6 – Number of Patents versus Revenue for Highlighted Companies .258Figure 1.7 – Litigation Analysis ..259Table 1.1 – Table of Highlighted Companies and Technologies .2602.0 INTRODUCTION .2623.0 TECHNOLOGY .264Figure 3.1 – Diabetes Landscape by Technology .265Figure 3.2 – Self Monitoring of Blood Glucose 266Figure 3.3 – Blood Glucose Test Strip Operation 267Figure 3.4 – Continuous Glucose Monitoring (CGM) .267Figure 3.5 – Artificial Pancreas Representative Diagram 2694.0 OVERVIEW OF PATENT ACTIVITIES .270Figure 4.1 – High Level Overview of Diabetes Patent Activity .2714.1 Analysis of Patents Sorted by this Study .273Figure 4.2 – Bar Chart of Totals for each Technology Group .273Figure 4.3 – Top 20 Assignees Patents from This Study .274Figure 4.4 – Patents by Priority Date 275Figure 4.5 – Priority Date by Top 5 Companies ..276Figure 4.6 – Patents by Published Date .277Figure 4.7 – Patents by Source Jurisdiction ..278Figure 4.8 – Top 10 IPC Codes from the Patents Analyzed ..279Figure 4.9 – Total U.S. Patents by Assignee ..280Figure 4.10 – USP Classification Analysis within the U.S. Dataset ..2815.0 PATENT ANALYSIS BY TECHNOLOGY SUBCATEGORY 2825.1 Detection and Monitoring – Periodic – Invasive – Blood Extraction .283Figure 5.1 – Blood Extraction – Top Assignees ..283Priority Date by Year and Source: 284Figure 5.2 - Blood Extraction by Priority Date .284Priority Date by Year by Top 5 Assignees within the Subcategory: 285Figure 5.3 - Blood Extraction by Priority Date by Assignee .285Published Date by Year and Source: ..286Figure 5.4 - Blood Extraction by Published Date 286IPC Analysis – Top 10 Codes: .287Figure 5.5 - Blood Extraction by IPC Code 287USPC Analysis – Top 10 Codes: 288Figure 5.6 - Blood Extraction by USPC Code ..288Figure 5.7 – Blood Extraction - Text Clustering Analysis .289Source Jurisdiction: 290Figure 5.8 - Blood Extraction by Source Jurisdiction .290Top Patents .291Table 5.1 - Top Patents Identified in the Blood Extraction Group .291US6461496B1: Abbott Laboratories 292Figure 5.9 – Representative Image in US6461496 ..292Figure 5.10 – Top 20 Companies Citing US6461496 .293US5916230A: Bayer AG 294Figure 5.11 – Representative Images of US5916230 .294Figure 5.12 – Top 20 Companies Citing US5916230 2955.2 Detection and Monitoring – Periodic – Invasive – Test Strips .296Figure 5.13 – Test Strips – Top Assignees .296Priority Date by Year and Source: 297Figure 5.14 - Test Strips by Priority Date .297Priority Date by Year by Assignee: 297Figure 5.15 - Test Strips by Priority Date by Assignee 297Published Date by Year: .298Figure 5.16 - Test Strips by Published Date .298IPC Analysis – Top 10 Codes: .299Figure 5.17 - Test Strips by IPC Code 299USPC Analysis – Top 10 Codes: 300Figure 5.18 - Test Strips by USPC Code .300Text Clustering Analysis: 301Figure 5.19 – Test Strips - Text Clustering Analysis ..301Source Jurisdiction: 302Figure 5.20 - Test Strips by Source Jurisdiction 302Top Patents .303Table 5.2 - Top Patents Identified in the Test Strips Group ..303US5496453A: Arkray, Inc. .304Figure 5.21 – Representative Image in US5496453 304Figure 5.22 – Top 20 Companies Citing US5496453 .305US5563042: Johnson & Johnson .306Figure 5.23 – Representative Image in US5563042 306Figure 5.24 – Top 20 Companies Citing US5563042 .3075.3 Detection and Monitoring – Periodic – Invasive – Devices 308Figure 5.25 – Devices – Top Assignees ..308Priority Date by Year: .309Figure 5.26 - Devices by Priority Date 309Priority Date by Year by Assignee: 309Figure 5.27 - Devices by Priority Date by Assignee ..309Published Date by Year and Source: 310Figure 5.28 - Devices by Published Date .310IPC Analysis – Top 10 Codes: 311Figure 5.29 - Devices by IPC Code 311USPC Analysis – Top 10 Codes: .312Figure 5.30 - Devices by USPC Code 312Text Clustering Analysis: .313Figure 5.31 – Devices - Text Clustering Analysis .313Source Jurisdiction: .314Figure 5.32 - Devices by Source Jurisdiction ..314Top Patents 315Table 5.3 - Top Patents Identified in the Devices Group .315US6233471: Johnson & Johnson .316Figure 5.33 – Representative Image in US6233471 316Figure 5.34 – Top 20 Companies Citing US6233471 .3175.4 Detection and Monitoring – Periodic – Minimally Invasive – Interstitial Fluid .318Figure 5.35 – Interstitial Fluid – Top Assignees .318Priority Date by Year: 319Figure 5.36 - Interstitial Fluid by Priority Date 319Priority Date by Year by Assignee: .319Figure 5.37 - Interstitial Fluid by Priority Date 319Published Date by Year: .320Figure 5.38 - Interstitial Fluid by Published Date .320IPC Analysis - Top 10 Codes: 321Figure 5.39 - Interstitial Fluid by IPC Code 321USPC Analysis – Top 10 Codes: 322Figure 5.40 - Interstitial Fluid by USPC Code ..322Text Clustering Analysis: 323Figure 5.41 – Interstitial Fluid - Text Clustering Analysis .323Source Jurisdiction: 324Figure 5.42 - Interstitial Fluid by Source Jurisdiction .324Top Patents .325Table 5.4 - Top Patents Identified in the Interstitial Fluid Group 325US5582184: Alere Incorporated .326Figure 5.43 – Representative Image in US5582184 326Figure 5.44 – Top 20 Companies Citing US5582184 .3275.5 Detection and Monitoring – Periodic – Minimally Invasive – Skin Diffusion ..328Figure 5.45 – Skin Diffusion – Top Assignees .328Priority Date by Year: .329Figure 5.46 - Skin Diffusion by Priority Date .329Priority Date by Year by Assignee: 329Figure 5.47 - Skin Diffusion by Priority Date by Assignee .329Published Date by Year: .330Figure 5.48 - Skin Diffusion by Published Date ..330IPC Analysis – Top 10 Codes: .331Figure 5.49 - Skin Diffusion by IPC Code .331USPC Analysis – Top 10 Codes: 332Figure 5.50 - Skin Diffusion by USPC Code 332Text Clustering Analysis: 333Figure 5.51 – Skin Diffusion - Text Clustering Analysis 333Source Jurisdiction: 334Figure 5.52 - Skin Diffusion by Source Jurisdiction ..334Top Patents .334Table 5.5 - Top Patents Identified in the Skin Diffusion Group .334US6454710: Johnson & Johnson .335Figure 5.53 – Representative Image in US6454710 335Figure 5.54 – Top 20 Companies Citing US6454710 .3365.6 Detection and Monitoring – Periodic – Non Invasive – Optical .337Figure 5.55 – Non Invasive - Optical – Top Assignees .337Priority Date by Year: .338Figure 5.56 - Non Invasive - Optical by Priority Date .338Priority Date by Year by Assignee: 338Figure 5.57 - Non Invasive - Optical by Priority Date .338Published Date by Year: .339Figure 5.58 - Non Invasive - Optical by Published Date 339IPC Analysis – Top 10 Codes: .340Figure 5.59 - Non Invasive - Optical by IPC Code 340USPC Analysis – Top 10 Codes: 341Figure 5.60 - Non Invasive - Optical by USP Class Code 341Text Clustering Analysis: 342Figure 5.61 – Non Invasive - Optical - Text Clustering Analysis .342Source Jurisdiction: 343Figure 5.62 - Non Invasive - Optical by Source Jurisdiction .343Top Patents .344Table 5.6- Top Patents Identified in the Non Invasive Optical Group 344US5743262: Masimo Corporation 345Figure 5.63 – Representative Image in US5743263 345Figure 5.64 – Top 20 Companies Citing US5743263 346US6040578: Sensys Medical Inc 347Figure 5.65 – Patent Diagram of US6040578 .347Figure 5.66 – Top 20 Companies Citing US6040578 .3485.7 Detection and Monitoring – Periodic – Non Invasive – Other 349Figure 5.67 – Non-Invasive Other – Top Assignees 349Priority Date by Year: .350Figure 5.68 – Non-Invasive Other by Priority Date .350Priority Date by Year by Assignee: 350Figure 5.69 - Non-Invasive Other by Priority Date by Assignee 350Published Date by Year: .351Figure 5.70 - Non-Invasive Other by Published Date 351IPC Analysis – Top 10 Codes: .352Figure 5.71 - Non Invasive Other by IPC Code 352USPC Analysis – Top 10 Codes: 353Figure 5.72 - Non Invasive Other by USPC Code ..353Text Clustering Analysis: 354Figure 5.73 – Non Invasive Other - Text Clustering Analysis .354Source Jurisdiction: 355Figure 5.74 – Non-Invasive - Other by Source Jurisdiction .355Top Patents .355Table 5.7 - Top Patents Identified in the Non Invasive – Other Group .355US6572542: Medtronic Inc .356Figure 5.75 – Representative Image in US6572542 356Figure 5.76 – Top 20 Companies Citing US6572542 .3575.8 Detection and Monitoring – Continuous – Non-Implanted .358Figure 5.77 – Continuous Non-Implanted – Top Assignees .358Priority Date by Year: .359Figure 5.78 - Continuous Non-Implanted by Priority Date .359Priority Date by Year by Assignee: 359Figure 5.79 - Continuous Non-Implanted by Priority Date by Assignee 359Published Date by Year: .360Figure 5.80 - Continuous Non-Implanted by Published Date ..360IPC Analysis – Top 10 Codes: .361Figure 5.81 - Continuous Non-Implanted by IPC Code .361USPC Analysis – Top 10 Codes: 362Figure 5.82 - Continuous Non-Implanted by USPC Code .362Figure 5.83 – Continuous Non-Implanted -Text Clustering Analysis 363Source Jurisdiction: 364Figure 5.84 - Continuous Non-Implanted by Source Jurisdiction 364Top Patents .365Table 5.8 - Top Patents Identified in the Continuous Non-Implanted Group 365US6931327: Dexcom, Inc. ..366Figure 5.85 – Representative Image in US6931327 366Figure 5.86 – Top 20 Companies Citing US6931327 3675.9 Detection and Monitoring – Continuous – Implanted .368Figure 5.87 – Continuous Implanted – Top Assignees 368Priority Date by Year: .369Figure 5.88 - Continuous Implanted by Priority Date ..369Priority Date by Year by Assignee: 369Figure 5.89 - Continuous Implanted by Priority Date by Assignee ..369Published Date by Year: .370Figure 5.90 - Continuous Implanted by Published Date .370IPC Analysis – Top 10 Codes: .371Figure 5.91 - Continuous Implanted by IPC Code .371USPC Analysis – Top 10 Codes: 372Figure 5.92 - Continuous Implanted by USPC Code .372Text Clustering Analysis: 373Figure 5.93 – Continuous Implanted - Text Clustering Analysis 373Source Jurisdiction: .374Figure 5.94 - Continuous Implanted by Source Jurisdiction 374Top Patents .375Table 5.9 - Top Patents Identified in the Continuous Implanted Group .375Figure 5.95 – Representative Image in US6001067 376Figure 5.96 – Top 20 Companies Citing US6001067 .3775.10 Treatment – Manual – Syringe 378Figure 5.97 – Syringe – Top Assignees 378Priority Date by Year: .379Figure 5.98 - Syringe by Priority Date 379Prior To order this report: Pathology Industry: Diabetes Landscape: Market, Technology and Intellectual Property __________________________Contact Clare: email@example.com US:(339) 368 6001 Intl:+1 339 368 600 SOURCE Reportlinker